Background information:About the study CALMAGThe CALMAG study is a 24-week.

Background information:About the study CALMAGThe CALMAG study is a 24-week, randomized, controlled, multicenter, head – to-head clinical trial comparing the efficacy of two phosphate binders.

The poster presented: – 29 October 2009, 10 – 12 clock – Poster Board: TH-PO615 – Lead Investigator: Prof. Angel Luis Mart n de Francisco, Universidad de Cantabria, Santander .’Investment in the CALMAG study our commitment to the best treatment for dialysis patients emphasizes ‘said Dr. Emanuele Gatti, Chief Executive Officer of Fresenius Medical Care for the regions of Europe, Latin America, Middle East and Africa. ‘These results bring us one step closer to our goal of an integrated care.For the study, Robins and colleague the effectiveness of higher -throughput sequencing towards the flow cytometry to the minimal residual disease in 43 patients with acute T lymphocytic leukemia, a type of blood cancer that is most common in children under 7 diagnosed with detect comparison. Through sequencing to the patient’s T-cell OR genes ago and 29 days after the chemotherapy, researchers were able to to accurately measure their attendance blood and more accurate prediction from Leukaemia dropout.

Robin and colleagues discovered how of sequencing it traditional high-throughput technological customize simply variable regions of genetic counseling of the T – and B. Cell receptors. A critical component in the human adaptive immunity These receptors have quick DNA strands of, the arrange constantly, order immune system combating against virus, infection or disease.